Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Didroxyprogesterone
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Didroxyprogesterone is a synthetic progestogen, described as being the closest to natural progesterone. It is being investigated for its role in promoting natural pregnancy in infertile patients with endometriosis, where it is believed to inhibit endometriosis recurrence without affecting ovulation or harming embryos. It has also been studied for its potential to reduce pregnancy loss in threatened abortion and to prevent recurrence of endometrial polyps after IVF-ET failure. Additionally, it is a component of combination therapies, such as Fenmotong, used in the treatment of decreased ovarian reserve function.
- Other names
- DG
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on Didroxyprogesterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Didroxyprogesterone.